Future studies should also focus on the growing need for affordable and accessible interventions in low-resource settings to improve outcomes for metastatic breast cancer patients, including enhanced diagnostic capabilities and equitable access to systemic therapies targeting specific cancer subtypes, particularly HER-2/neu+ and hormone receptor-positive breast cancers. This evidence concerns the gene ERBB2 and cancer.